Short Interest in Franklin Genomic Advancements ETF (BATS:HELX) Rises By 108.6%

Franklin Genomic Advancements ETF (BATS:HELX) was the target of a large increase in short interest in June. As of June 30th, there was short interest totaling 15,981 shares, an increase of 108.6% from the June 15th total of 7,660 shares. Based on an average trading volume of 4,418 shares, the days-to-cover ratio is presently 3.6 days. Currently, 4.0% of the company’s stock are short sold.

Franklin Genomic Advancements ETF Stock Down 1.2%

Shares of Franklin Genomic Advancements ETF stock opened at $39.24 on Friday. Franklin Genomic Advancements ETF has a 52 week low of $26.99 and a 52 week high of $41.30. The business has a 50 day moving average price of $36.56 and a 200-day moving average price of $35.33. The company has a market cap of $15.70 million, a PE ratio of 26.71 and a beta of 1.05.

Hedge Funds Weigh In On Franklin Genomic Advancements ETF

Large investors have recently bought and sold shares of the stock. Kestra Advisory Services LLC purchased a new position in Franklin Genomic Advancements ETF during the 4th quarter worth $39,000. LPL Financial LLC grew its position in Franklin Genomic Advancements ETF by 22.4% in the 4th quarter. LPL Financial LLC now owns 11,133 shares of the company’s stock worth $404,000 after purchasing an additional 2,037 shares in the last quarter. Osaic Holdings Inc. increased its stake in Franklin Genomic Advancements ETF by 19.1% in the 2nd quarter. Osaic Holdings Inc. now owns 3,132 shares of the company’s stock valued at $87,000 after buying an additional 502 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Franklin Genomic Advancements ETF in the 2nd quarter worth approximately $42,000.

Franklin Genomic Advancements ETF Company Profile

The Franklin Genomic Advancements ETF (HELX) is an exchange-traded fund that is based on the Solactive Genomics index. The fund is an actively managed portfolio of global equity securities of companies relevant to genomic discovery. HELX was launched on Feb 25, 2020 and is managed by Franklin Templeton.